PROSPECTUS SUMMARY
This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus (as supplemented and amended), including the financial data and related notes, risk factors and
other information incorporated by reference in this prospectus before making an investment decision.
Unless the context indicates
otherwise, as used in this prospectus, the terms Ziopharm, the Company, we, us and our refer to Ziopharm Oncology, Inc., a Delaware corporation. This prospectus or information incorporated
by reference in this prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to or incorporated by reference in this prospectus, including logos,
artwork and other visual displays, may appear without the
®
or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the
fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
About Ziopharm Oncology
We are a biopharmaceutical company focused on discovering, acquiring, developing and commercializing next generation immunotherapy platforms
that leverage gene- and cell-based therapies to treat patients with cancer. We are developing two immuno-oncology platform technologies designed to utilize the patients immune system by employing novel, controlled gene expression and
innovative cell engineering technologies to deliver safe, effective, and scalable cell- and viral-based therapies for the treatment of multiple cancer types. Our first platform is Controlled
IL-12,
which is
designed to deliver interleukin 12 or
IL-12,
a master regulator of the immune system, in a controlled and safe manner to focus the patients immune system to cancer. Our second platform is referred to as
Sleeping Beauty
and is based on the genetic engineering of immune cells using the
Sleeping Beauty
system to rapidly reprogram T cells outside of the body for subsequent infusion. We believe these two platforms provide or will provide
unique and powerful solutions intended to advance the field of immuno-oncology and address the issues associated with (1) treating heterogenous solid tumors and unknown antigens therein through control of
IL-12
and (2) providing rapid and cost-effective manufacturing solutions for CAR and
TCR-based
cell therapies for hematologic malignancies and solid tumors against
known antigens.
We are developing a gene therapy that delivers Controlled
IL-12
to treat patients
with solid tumors including brain cancer. Based on technology licensed from MD Anderson Cancer Center, we are developing CAR
T-cell
or CAR+ T targeting CD19, and
T-cell
receptor
T-cell,
or TCR+ T, therapies. These programs are being advanced in collaboration with MD Anderson and the National Cancer Institute, or NCI.
Corporate Information
We
originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to EasyWeb, Inc. in February 1999.
We re-incorporated in
Delaware on
May 16, 2005 under the same name. On September 13, 2005, we completed a reverse acquisition of privately held Ziopharm, Inc., a Delaware corporation. To affect this transaction, we caused ZIO Acquisition Corp., our wholly-owned
subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. In accordance with the terms of the merger, the outstanding common stock of Ziopharm, Inc. automatically converted into the right to
receive an aggregate of approximately 97.3% of our outstanding common stock (after giving effect to the transaction). Following the merger, we caused Ziopharm, Inc. to merge